About: Armetheon is a cardiovascular focused late-clinical stage specialty pharmaceutical company developing a potentially best-in-class, novel, orally active anticoagulant (tecarfarin) for all patients who need an oral anticoagulant including a targeted patient population with major unmet need. Unlike non-monitored oral anti-coagulant (NOAC) The second drug candidate under development is budiodarone which is an oral Phase 2 clinical-stage drug candidate that is being investigated for its potential to suppress ventricular arrhythmias and device firing in patients with implantable cardioverter defibrillators (ICDs) and for the treatment of patients with refractory Afib. In Q2, 2017, Armetheon agreed to merge with Espero Pharmaceuticals, to create Espero Biopharma, a cardiovascular focused commercial stage pharmaceuticals company with marketed products and a potential blockbuster pipeline. The merger was completed in Q3, 2017. www.esperobio.com Founded: October, 2011 (Sunnyvale, CA) Total funds raised; $33 MM Other Investors: Capital TEN II, Hercules Bioventures, CDIB Healthcare, CDIB & Partners, AshHill Biomedical Investments, iD SoftCapital, AmKey Ventures, Lee’s Pharmaceutical (Hong Kong) and eminent biotech entrepreneurs and pharmaceutical executives. Lee’s Pharmaceutical (Hong Kong)